Eosinophilic enteropathy: Clinical Trials

7 trials for Eosinophilic enteropathy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 terminated, 1 withdrawn. 7 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Completed 5, Terminated 1, Withdrawn 1
Phase 21Completed 1

Follow Eosinophilic enteropathy: new trials by email Literature Review of Eosinophilic enteropathy trials Research Report on Eosinophilic enteropathy

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis
CC-93538, Placebo - Eosinophilic Gastroenteritis
Phase 3CompletedCelgene482022-03-042026-09-14
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
Benralizumab, Placebo - Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Phase 3TerminatedAstraZeneca122022-01-182025-07-14
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis
Phase 3WithdrawnAllakos Inc.2021-12-012023-03-03
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
AK002, Placebo - Eosinophilic Duodenitis, Eosinophilic Gastroenteritis
Phase 3CompletedAllakos Inc.942021-05-202024-01-02
An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
lirentelimab - Eosinophilic Gastritis, Eosinophilic Duodenitis
Phase 3CompletedAllakos Inc.1592020-12-032024-04-22
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
lirentelimab (AK002), Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis
Phase 3CompletedAllakos Inc.1812020-06-182024-01-02
Benralizumab for Eosinophilic Gastritis (BEGS)
Benralizumab, Placebo - Eosinophilic Gastritis or Gastroenteritis
Phase 2 / Phase 3CompletedChildren's Hospital Medical Center, Cincinnati262018-04-232022-02-03

Narrower conditions

Eosinophilic Esophagitis (3)  ·  Gastroenteritis (3)  ·  Digestive System Diseases (2)  ·  Gastrointestinal Diseases (2)  ·  Intestinal Diseases (1)  ·  Stomach Diseases (1)

Broader conditions

Digestive System Diseases (4)  ·  Gastrointestinal Diseases (4)  ·  Eosinophilia (3)  ·  Esophageal Diseases (3)  ·  Esophagitis (3)  ·  Gastroenteritis (3)  ·  Hematologic Diseases (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Hypersensitivity (3)  ·  Hypersensitivity, Immediate (3)  ·  Immune System Diseases (3)  ·  Leukocyte Disorders (3)

Interventions

AK002 (4)  ·  benralizumab (2)  ·  cendakimab (1)

Sponsors

Allakos Inc. (4)  ·  AstraZeneca (1)  ·  Celgene (1)  ·  Children's Hospital Medical Center, Cincinnati (1)

Countries

United States (6)  ·  Japan (2)  ·  Brazil (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Spain (1)  ·  Ukraine (1)  ·  Vietnam (1)

Top investigators

Craig Paterson, MD (3)  ·  Craig Patterson, MD (1)  ·  Marc E Rothenberg, MD, PhD (1)  ·  Marc E. Rothenberg, MD, PhD (1)

Results publications

PMID 37336228